{"nctId":"NCT01358864","briefTitle":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)","startDateStruct":{"date":"2011-06"},"conditions":["Hepatitis C, Chronic"],"count":678,"armGroups":[{"label":"Placebo/PegIFN/RBV","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pegylated Interferon-alpha (IFN)","Drug: Ribavirin (RBV)","Drug: Placebo"]},{"label":"BI201335 12 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: BI 201335","Drug: Pegylated Interferon-alpha (IFN)","Drug: Ribavirin (RBV)"]},{"label":"BI201335 24 weeks","type":"EXPERIMENTAL","interventionNames":["Drug: BI 201335","Drug: Pegylated Interferon-alpha (IFN)","Drug: Ribavirin (RBV)"]}],"interventions":[{"name":"BI 201335","otherNames":[]},{"name":"Pegylated Interferon-alpha (IFN)","otherNames":[]},{"name":"Ribavirin (RBV)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Chronic hepatitis C genotype 1 infection, diagnosed at least 6 months prior to screening\n2. Confirmed prior virological failure with an approved dose of PegIFN/RBV\n3. Age 18 to 70 years,\n4. HCV RNA (RiboNucleic Acid) = 1,000 IU/mL at screening,\n\nExclusion criteria:\n\n1. HCV infection of mixed genotype; Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV) co-infection\n2. Evidence of acute or chronic liver disease due to causes other than chronic HCV infection,\n3. Decompensated liver disease, or history of decompensated liver disease,\n4. Body weight \\< 40 or \\> 125 kg,\n5. Clinical evidence of significant or unstable cardiovascular disease, chronic pulmonary disease, history or evidence of retinopathy or clinically significant ophthalmological disorder\n6. Pre-existing psychiatric condition that could interfere with the subject's participation in and completion of the study\n7. Laboratory parameters disorders (thalassemia major, sickle cell anemia or G6PD deficit)\n8. Hemoglobin \\< 12 g/dL for women and \\< 13 g/dL for men\n9. Patients who have been previously treated with at least one dose of any antiviral or immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic HCV infection including and not restricted to protease or polymerase inhibitors,","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Virological Response After 24 Weeks of Treatment Discontinuation (SVR24)","description":"Percentage of participants with virological response after 24 weeks of treatment discontinuation (SVR24) defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level \\<25 IU/mL (undetected) 24 weeks after the originally planned treatment duration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"63.5","spread":null},{"groupId":"OG002","value":"59.5","spread":null},{"groupId":"OG003","value":"33.8","spread":null},{"groupId":"OG004","value":"32.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Success (ETS)","description":"Percentage of participants with early Treatment Success (ETS) defined as a plasma HCV RNA level \\<25 IU/mL (undetected or detected) at Week 4 and \\<25 IU/mL (undetected) at Week 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"85.9","spread":null},{"groupId":"OG002","value":"87.4","spread":null},{"groupId":"OG003","value":"3.4","spread":null},{"groupId":"OG004","value":"66.7","spread":null},{"groupId":"OG005","value":"76.4","spread":null},{"groupId":"OG006","value":"58.6","spread":null},{"groupId":"OG007","value":"51.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Sustained Virological Response 12 Weeks Post Treatment (SVR12)","description":"Percentage of participants with sustained virological response (SVR12) 12 weeks post treatment defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level \\<25 IU/mL (undetected) 12 weeks after the originally planned treatment duration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"65.4","spread":null},{"groupId":"OG002","value":"61.4","spread":null},{"groupId":"OG003","value":"33.8","spread":null},{"groupId":"OG004","value":"32.9","spread":null}]}]}]},{"type":"SECONDARY","title":"ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=NO","description":"The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment (EoT) when patients do not have sustained virological response 12 weeks post treatment. BL=baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"28","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"30","spread":null},{"groupId":"OG006","value":"96","spread":null},{"groupId":"OG007","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"15","spread":null},{"groupId":"OG007","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"14","spread":null},{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"34","spread":null},{"groupId":"OG007","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=YES","description":"The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"33","spread":null},{"groupId":"OG005","value":"25","spread":null},{"groupId":"OG006","value":"49","spread":null},{"groupId":"OG007","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"10","spread":null},{"groupId":"OG005","value":"8","spread":null},{"groupId":"OG006","value":"12","spread":null},{"groupId":"OG007","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"14","spread":null},{"groupId":"OG005","value":"8","spread":null},{"groupId":"OG006","value":"23","spread":null},{"groupId":"OG007","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=NO","description":"The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"28","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"30","spread":null},{"groupId":"OG006","value":"96","spread":null},{"groupId":"OG007","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"5","spread":null},{"groupId":"OG006","value":"18","spread":null},{"groupId":"OG007","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"14","spread":null},{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"24","spread":null},{"groupId":"OG007","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=YES","description":"The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment (EoT) when patients have sustained virological response 12 weeks post treatment. BL=baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"33","spread":null},{"groupId":"OG005","value":"25","spread":null},{"groupId":"OG006","value":"49","spread":null},{"groupId":"OG007","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"13","spread":null},{"groupId":"OG005","value":"10","spread":null},{"groupId":"OG006","value":"15","spread":null},{"groupId":"OG007","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"10","spread":null},{"groupId":"OG005","value":"9","spread":null},{"groupId":"OG006","value":"21","spread":null},{"groupId":"OG007","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, When SVR12=NO","description":"The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"28","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"30","spread":null},{"groupId":"OG006","value":"96","spread":null},{"groupId":"OG007","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"11","spread":null},{"groupId":"OG007","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"23","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"5","spread":null},{"groupId":"OG006","value":"27","spread":null},{"groupId":"OG007","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, SVR12=YES","description":"The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"33","spread":null},{"groupId":"OG005","value":"25","spread":null},{"groupId":"OG006","value":"49","spread":null},{"groupId":"OG007","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"13","spread":null},{"groupId":"OG005","value":"10","spread":null},{"groupId":"OG006","value":"13","spread":null},{"groupId":"OG007","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"20","spread":null},{"groupId":"OG005","value":"11","spread":null},{"groupId":"OG006","value":"32","spread":null},{"groupId":"OG007","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, When SVR12=NO","description":"The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"28","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"30","spread":null},{"groupId":"OG006","value":"96","spread":null},{"groupId":"OG007","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"13","spread":null},{"groupId":"OG007","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"6","spread":null},{"groupId":"OG007","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"23","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"27","spread":null},{"groupId":"OG007","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, SVR12=YES","description":"The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"33","spread":null},{"groupId":"OG005","value":"25","spread":null},{"groupId":"OG006","value":"49","spread":null},{"groupId":"OG007","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"16","spread":null},{"groupId":"OG005","value":"13","spread":null},{"groupId":"OG006","value":"16","spread":null},{"groupId":"OG007","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"16","spread":null},{"groupId":"OG005","value":"8","spread":null},{"groupId":"OG006","value":"28","spread":null},{"groupId":"OG007","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":78},"commonTop":["Nausea","Pruritus","Fatigue","Headache","Diarrhoea"]}}}